Markets:

Overview

News

Currencies

International

Treasuries

Pfizer (NY:PFE)

27.55 -0.17 (-0.61%)

Official Closing Price Updated: 7:00 PM EDT, Sep 15, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Pfizer

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Explore the S&P500 index on Tuesday and find out which stocks are the most active in today's session. ↗

Today 14:05 EDT

Via Chartmill

IP Group H1 Earnings Call Highlights ↗

Today 7:03 EDT

IP Group (LON:IPO) reported higher net asset value, strong cash realizations and broad portfolio activity in the first half of 2026, while management said it remains focused on converting portfolio...

Via MarketBeat

Topics Earnings Initial Public Offering

Alnylam's Sell-Off Looks Ugly -- but Wall Street Still Sees a Much Brighter Picture ↗

Today 5:04 EDT

Analysts think Alnylam could rebound strongly over the next 12 months.

Via The Motley Fool

Pfizer Says Major Headwinds Are Easing as Pipeline, Obesity Plans Take Center Stage ↗

September 14, 2026

Pfizer (NYSE:PFE) Chairman and Chief Executive Officer Albert Bourla said the drugmaker has addressed several major headwinds that weighed on investor attention, including policy uncertainty, declining...

Via MarketBeat

Topics Intellectual Property World Trade

3 Healthcare Stocks That Fall Short

September 14, 2026

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advanceme...

Via StockStory

How Concerned Should Income Investors Be About Pfizer's Dividend? ↗

September 12, 2026

Pfizer has a huge 6% yield and a payout ratio well over 100%, yet the company is still maintaining the dividend.

Via The Motley Fool

Topics Intellectual Property

Regeneron Eyes 2026 Catalysts as EYLEA HD and DUPIXENT Drive Growth ↗

September 12, 2026

Regeneron Pharmaceuticals (NASDAQ:REGN) executives outlined plans for continued growth across its commercial portfolio, upcoming regulatory milestones and pipeline programs during a Wells Fargo...

Via MarketBeat

Topics ETFs

1 Oversold Stock Ready to Bounce Back and 2 Facing Challenges

September 11, 2026

Rock-bottom prices don’t always mean rock-bottom businesses. The stocks we’re examining today have all touched their 52-week lows, creating a classic investo...

Via StockStory

Novavax Highlights Sanofi, Pfizer Catalysts in Matrix-M Platform Pivot ↗

September 10, 2026

Novavax (NASDAQ:NVAX) executives outlined the company’s transition from a COVID-19 vaccine-focused business toward a partnership-driven model centered on its Matrix-M adjuvant technology, with...

Via MarketBeat

Why Pfizer Stock Was so Healthy in August ↗

September 08, 2026

The beaten-down pharmaceutical stock was revived after it posted an estimates-beating quarter.

Via The Motley Fool

Topics Intellectual Property

Move Aside, Pfizer: This Stock Is the Smarter Dividend Buy Right Now ↗

September 08, 2026

Pfizer's 6% dividend yield is enticing, but AbbVie's dividend growth is superior.

Via The Motley Fool

Topics Intellectual Property

Eli Lilly Has Been on an Acquisition Spree. How Much Could Its Latest Deals Boost the Stock? ↗

September 07, 2026

The big story today with Eli Lilly is its hugely successful GLP-1 drugs, but the long-term story is likely to be about its acquisitions.

Via The Motley Fool

This Is What I'd Do With Pfizer Stock Right Now ↗

September 07, 2026

The pharmaceutical stock is struggling, but its dividend can be highly valuable to income investors.

Via The Motley Fool

Topics Intellectual Property

AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? ↗

September 04, 2026

AbbVie's immunology pivot is offsetting Humira's decline, while Pfizer trades at half the valuation despite patent risks ahead.

Via The Motley Fool

Topics Intellectual Property

3 Things You Need to Know If You Buy Pfizer Stock Today ↗

September 03, 2026

After a long bout with poor post-pandemic performance, the stock's starting to perk up. The question is, are other investors -- and analysts -- willing to stick their neck out any further anytime...

Via The Motley Fool

Topics Intellectual Property

Medicus Pharma Inks Global Licensing Deal with Pfizer Worth Over $1 Billion ↗

September 03, 2026

Medicus Pharma partners with Pfizer to commercialize CD228V in a licensing deal worth over $1 billion plus royalties.

Via Benzinga

Is BioNTech Stock a No-Brainer Buy on the Dip? ↗

September 02, 2026

The company is coming back into the spotlight thanks to recent developments.

Via The Motley Fool

Wednesday's session: most active stock in the S&P500 index ↗

September 02, 2026

Via Chartmill

Should You Buy Pfizer Stock Below $30? ↗

September 02, 2026

Patient investors who buy the stock may be rewarded over the long term.

Via The Motley Fool

Topics Earnings Intellectual Property

2 Absurdly Cheap Dividend Stocks to Buy With $1,000 Right Now ↗

September 02, 2026

If you're looking to invest $1,000 in a dividend stock, look to the pharmaceutical sector.

Via The Motley Fool

Top Companies Using Salesforce CRM in the USA ↗

September 02, 2026

Salesforce powers the engine behind America’s most ambitious brands. From retail giants to global banks, its footprint is massive. Therefore, marketers eve

Via Talk Markets

Curious about the most active S&P500 stocks in today's session? ↗

September 01, 2026

Via Chartmill

Stay informed about the most active stocks in the S&P500 index on Monday's session. ↗

August 31, 2026

Via Chartmill

3 Stocks for Investors Who Still Believe Cash Is King ↗

August 31, 2026

As investors hedge against AI-trade valuation worries, dividend payers gain favor. AT&T, ONEOK, and Pfizer offer yields from 4.3% to 6.1% with distinct capital-return strategies.

Via MarketBeat

Topics Artificial Intelligence ETFs Economy

3 Cash-Producing Stocks That Concern Us

August 31, 2026

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff...

Via StockStory

Should Eli Lilly Investors Be Worried About a Threat From Amylyx? ↗

August 30, 2026

Eli Lilly is currently leading the GLP-1 market, but Amylyx is seeing strong results from its GLP-1 drug candidate.

Via The Motley Fool

Amgen vs. Axsome Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? ↗

August 29, 2026

Amgen generated $8.1 billion in free cash flow in 2025, with a 21% net margin, while Axsome is scaling rapidly but still unprofitable.

Via The Motley Fool

2 Cash-Producing Stocks with Solid Fundamentals and 1 We Turn Down

August 28, 2026

A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Luc...

Via StockStory

QUICK SPARK: FDA Approves Updated COVID Vaccines From Moderna, Pfizer, Novavax ↗

August 27, 2026

FDA approves updated COVID-19 vaccines for 2026-'27 season, targeting XFG variant. Limited eligibility for adults 65+ and those with high-risk conditions.

Via Benzinga

The Most Concerning Thing About Pfizer's Dividend Isn't What You Think ↗

August 27, 2026

Pfizer's payout ratio is above 100%, but that's not the number you should probably be watching right now.

Via The Motley Fool

Topics Intellectual Property

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.